ArticleGeroScience2026
Frailty elements, direct oral anticoagulants and mortality risk in atrial fibrillation patients aged ≥ 80 or ≥ 90 years from the nationwide Italian START registry: a propensity score matching analysis.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Navigating Anticoagulation Decisions in Atrial Fibrillation and Frailty Comorbidity.Life (Basel, Switzerland) · 2026Review
- Pharmacological rhythm control strategy and outcomes in the oldest atrial fibrillation patients: an analysis of the nationwide Italian START registry.Age and ageing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the use of direct oral anticoagulants (DOACs) in elderly frail patients with atrial fibrillation (AF). In 4244 patients aged ≥ 80 years and 533 aged ≥ 90 years from the nationwide START registry, we examined factors associated with DOACs use (vs warfarin) and its association with all-cause and cardiovascular (CV) death, CV events (CVEs) and bleeding. Propensity score-matching (PSM) analysis was also performed. Mean age was 84.8 years, 54.9% were women and 64% received DOACs. Frailty elements as tendency to falls (odds ratio [OR] 0.66, p = 0.030), living alone (OR 0.74, p = 0.027) and lack of familial/social support (OR 0.74, p < 0.001) were inversely associated with DOACs use, while wheelchair use was directly associated (OR 1.57, p = 0.014). During a mean of 686 ± 538 days follow-up, 492 all-cause deaths, 110 CV deaths, 548 CVEs and 221 bleedings occurred. Multivariable Cox regression and Fine-Gray analyses showed that DOAC use inversely associated with all-cause mortality (hazard ratio [HR] 0.35, p < 0.001), CV death (subdistribution HR [sHR] 0.43, p < 0.001), CVEs (sHR 0.46, p < 0.001) but not with bleeding. These associations were confirmed after PSM and persisted between sexes, in patients with Charlson Comorbidities Index > 5 or aged ≥ 90 years. At 24 months, the number needed to treat (NNT) for all-cause, CV death and CVEs were 11.0, 40.2 and 13.4. In patients aged ≥ 90 years, NNTs were 4.2, 4.5 and 12.0. In very elderly AF patients, DOACs prescription is influenced by frailty elements. DOACs inversely associated with mortality and CVEs risk independently from age, sex and comorbidities burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.